BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 20479932)

  • 21. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
    Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
    Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
    Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
    Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
    Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
    Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.
    Albino D; Longoni N; Curti L; Mello-Grand M; Pinton S; Civenni G; Thalmann G; D'Ambrosio G; Sarti M; Sessa F; Chiorino G; Catapano CV; Carbone GM
    Cancer Res; 2012 Jun; 72(11):2889-900. PubMed ID: 22505649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
    Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
    Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
    Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.
    Bowen C; Zheng T; Gelmann EP
    Cancer Res; 2015 Jul; 75(13):2686-98. PubMed ID: 25977336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic ETS Factors in Prostate Cancer.
    Nicholas TR; Strittmatter BG; Hollenhorst PC
    Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
    Zhang Q; Padi SK; Tindall DJ; Guo B
    Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.
    Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM
    Oncotarget; 2016 Nov; 7(47):76756-76768. PubMed ID: 27732936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
    Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
    Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells.
    Selvaraj N; Kedage V; Hollenhorst PC
    Cell Commun Signal; 2015 Feb; 13():12. PubMed ID: 25885538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.
    Lorenzoni M; De Felice D; Beccaceci G; Di Donato G; Foletto V; Genovesi S; Bertossi A; Cambuli F; Lorenzin F; Savino A; Avalle L; Cimadamore A; Montironi R; Weber V; Carbone FG; Barbareschi M; Demichelis F; Romanel A; Poli V; Del Sal G; Julio MK; Gaspari M; Alaimo A; Lunardi A
    Cancer Lett; 2022 May; 534():215612. PubMed ID: 35259458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.